Gland Pharma reported a strong Q2 FY26, with revenue increasing by 6% and profit after tax (PAT) growing by 12% year-over-year (YoY). The company anticipates robust growth in upcoming quarters driven by new launches and Cenexi’s recovery. Global CDMO expansion and capacity enhancement in high-end modalities are also expected to support sustainable growth and long-term value.
Financial Performance Highlights
Gland Pharma’s Q2 FY26 consolidated revenue from operations reached ₹14,869 million, a 6% increase compared to ₹14,058 million in Q2 FY25. Profit after tax (PAT) increased to ₹1,837 million, up 12% from ₹1,635 million in the same quarter last year. The company’s core business maintained a profitable growth trajectory with strong margin expansion.
For the first half of FY26, revenue grew by 7% and PAT increased by 30% YoY. The United States saw a 10% increase, and Europe grew by 16%, supported by a 21% top-line increase in Cenexi.
Segmental Performance
The base business (Gland) saw a 1% increase in revenue year-over-year, reaching ₹10,767 million. EBITDA increased by 3% to ₹3,755 million. Cenexi revenues were €40 million, an increase of 21%.
Key Business Updates
Gland Pharma launched seven new molecules in the USA during the quarter. Research and development expenses totaled ₹614 million, representing 5.8% of revenue. Six ANDA filings were made, and five ANDAs were approved. The company is aggressively increasing its GLP-1/Pen/cartridge capacity. During the shutdown, GMP certificate renewed through the end of CY2026 for Fontenay Facility.
Source: BSE
